SCHW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Charles Schwab Corp (SCHW) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The company's strong financial performance, positive analyst sentiment, and congress trading data indicating confidence in the stock outweigh the short-term technical and options data trends. Given the investor's scenario and focus on long-term growth, SCHW presents a solid investment opportunity.
The MACD is negative and contracting, RSI is neutral at 59.98, and moving averages are converging, indicating no strong trend. The stock's pre-market price is $96.75, down -0.69%, and key resistance levels are at $96.845 and $98.339, with support at $94.427 and $92.009. Short-term stock trend analysis suggests a potential decline of -0.36% in the next day and -6.15% in the next month.
Strong Q4 financial performance with revenue up 7.81% YoY, net income up 37.86% YoY, and EPS up 38.54% YoY.
Positive sentiment from congress trading data, with 3 purchase transactions and only 2 sales in the last 90 days.
Analysts have consistently raised price targets, with the highest being $138, indicating confidence in the company's future growth.
Broader market trends, such as the growth of money market funds and potential regulatory changes in retirement planning, could benefit Schwab's business model.
Short-term bearish technical indicators, including a negative MACD and potential for price declines in the next day and month.
Options data showing bearish sentiment with a put-call ratio above
Insider and hedge fund trading trends are neutral, showing no significant buying activity.
In Q4 2025, Charles Schwab reported strong financial growth: Revenue increased by 7.81% YoY to $7.17 billion, net income rose 37.86% YoY to $2.37 billion, EPS grew 38.54% YoY to $1.33, and gross margin improved by 10.28% to 88.39%. These metrics highlight robust profitability and operational efficiency.
Analysts maintain a positive outlook on SCHW, with multiple firms raising price targets recently. The highest target is $138 (TD Cowen), and the lowest is $94 (BofA, with an Underperform rating). Most analysts rate the stock as Buy or Overweight, citing strong net interest income, conservative 2026 guidance, and long-term growth potential.
